000D57 |
Jeffrey N. Joyce [États-Unis] ; Steve Presgraves [États-Unis] ; Lynn Renish [États-Unis] ; Sabinne Borwege [États-Unis] ; Tracy Osredkar [États-Unis] ; Diane Hagner [États-Unis] ; Maria Replogle [États-Unis] ; Mateo Pazsoldan [États-Unis] ; Mark J. Millan [France] | Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole |